Biosyngen Showcases Two Breakthrough In Vivo CAR-T Therapies, LV009 and LV091, at ASGCT 2026

RecentlyRecently, Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD announced that two core technological achievements of its self-developed in vivo CAR-T projects, LV009 Injection and LV091 Injection, have been successfully selected for poster presentation at the 2026 ASGCT Annual Meeting.

These two studies are based on Bo Sheng Ji's world-first CD7-VHH retargeting lentivirus in vivo CAR generation platform, achieving preclinical breakthrough progress in the fields of B-cell malignancies and autoimmune diseases respectively, demonstrating excellent preclinical efficacy and safety.Sex.

LV009 is the world's first highly efficient transfectionIn vivo CAR-T of resting T/NK cells,Preclinical data show:LV009 Exhibits Ultra-High Transfection Efficiency: GMP-grade LV009 achieves a transfection efficiency of over 50% in resting T cells derived from healthy donors and patients, with its efficiency unaffected by human serum interference; Unique Dual-Cell Generation Capability: It can directly transfect whole blood from healthy donors, simultaneously generating CAR-T and CAR-NK cells—a function not yet achieved by other global in vivo CAR technologies; Precise Targeting: Transfection strictly depends on CD7 expression, with no off-target effects observed in non-target cells such as primary B cells; Excellent In Vivo Anti-Tumor Activity: In humanized tumor-bearing mouse models, a single intravenous injection of LV009 efficiently generates CAR-T cells in vivo. CAR cell expansion peaks 15-20 days post-administration, with pharmacokinetic characteristics comparable to ex vivo manufactured CAR-T cells, significantly inhibiting tumor growth and prolonging mouse survival; Outstanding Safety: The virus is metabolized within 2 hours in vivo, with no off-target toxicity or histopathological damage found in critical organs such as the liver; Compared to the commonly used CD3-targeting strategy, CD7 targeting demonstrates superior safety features.

LV091 is the world's first dual-depletion in vivo CAR-T technology.，Bo Sheng Ji, based on the same CD7-VHH retargeting lentiviral platform, has developed LV091 injection specifically for autoimmune diseases, achieving a dual mechanism of action that simultaneously eliminates pathogenic B cells and abnormally activated PD1⁺ T cells in a single treatment.

Key preclinical data show:High Transfection Efficiency: The transfection efficiency for resting T cells derived from healthy donors exceeds 50%, and direct transfection of whole blood generates a CAR-T positivity rate of over 40%; Precise Dual-Targeting Functionality: In vitro experiments confirm that CD19/PD1 dual-specific CAR-T cells generated by LV091 exhibit significant and sustained specific cytotoxicity against both CD19⁺ target cells and PD1⁺ target cells; Validation with Patient Samples: Effectively depletes B cells in the peripheral blood of systemic lupus erythematosus (SLE) patients while specifically depleting the PD1⁺ T cell subset, with cytokine release demonstrating targeted specificity; In Vivo Efficacy: In humanized mouse models, a single intravenous infusion of LV091 not only significantly inhibits CD19⁺ tumor growth but also effectively eliminates overactivated PD1⁺ T cells; Excellent Safety Profile: No significant toxic reactions were observed throughout the experimental process, and mouse body weight remained stable.

Source of the article: Bo sheng ji Cell Research《Industry Express: Bo Sheng Ji's Two Breakthrough In Vivo CAR-T Technologies Debut at 2026 ASGCT Conference

If there is any infringement, please contact us to delete!